Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 51Lymphoid 33Breast 32Genitourinary 31Gastrointestinal 28Thoracic 24Sarcoma 22Head & Neck 20Dermatologic 20CNS 14Gynecologic 11Plasma cell 8Myeloid 7Other solid neoplasm 6Other neoplasm 6Classical hematology 3Tumor-Agnostic 1Endocrine 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Capecitabine 47Radiotherapy 46Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gene Expression Profiling × Tumor-Agnostic × Clear all
NCT03724097 2021-09-14

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

OmicsWay Corp.

Unknown
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡